Pediatric influenza immunization

Expert Review of Vaccines

Volumn 10, Issue 5, 2011, Pages 567-570

  Petrovsky, Nikolai ^a   Sajkov, Dimitar ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

adjuvant; childhood; influenza; pediatric; safety; vaccine

Indexed keywords

AZOXIMER BROMIDE; GRIPPOL; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; MIFAMURTIDE; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; CONSULTATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE CONVULSION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; MORTALITY; MYALGIA; NARCOLEPSY; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; VIRUS TRANSMISSION; WHEEZING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 79957594447     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.53     Document Type: Review

References (30)

1. Fowlkes AL, Arguin P, Biggerstaff MS et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin. Infect. Dis. 52(Suppl. 1), S60-S68 (2011).
2. Brotherton J, McIntyre P, Puech M et al. Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun. Dis. Intell. 28(Suppl. 2), VII-S116 (2004).
3. Wu JT, Ma ES, Lee CK et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin. Infect. Dis. 51(10), 1184-1191 (2010).
4. Bekker A, Chou C, Bernstein HH. Update on universal annual influenza immunization recommendations for children. Curr. Opin. Pediatr. 21(1), 122-126 (2009).
5. Dowdle WR, Millar JD, Schonberger LB, Ennis FA, LaMontagne JR. Influenza immunization policies and practices in Japan. J. Infect. Dis. 141(2), 258-264 (1980). (Pubitemid 10100306)
6. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344(12), 889-896 (2001). (Pubitemid 32224397)
7. Longini IM, Jr., Koopman JS, Haber M, Cotsonis GA. Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. Am. J. Epidemiol. 128(4), 845-859 (1988).
8. Elveback LR, Fox JP, Ackerman E, Langworthy A, Boyd M, Gatewood L. An influenza simulation model for immunization studies. Am. J. Epidemiol. 103(2), 152-165 (1976).
9. Lewis EN, Griffin MR, Szilagyi PG, Zhu Y, Edwards KM, Poehling KA. Childhood influenza: number needed to vaccinate to prevent 1 hospitalization or outpatient visit. Pediatrics 120(3), 467-472 (2007). (Pubitemid 47358287)
10. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. (2), CD004879 (2008).
11. Mullins RJ, Kemp A, Gold M. Influenza vaccination of the egg-allergic individual. Med. J. Aust. 193(5), 254-255 (2010).
12. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(®) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29(12), 2272-2278 (2011).
13. Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871-3878 (2007). (Pubitemid 46589748)
14. Landry N, Ward BJ, Trepanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010).
15. Frey S, Vesikari T, Szymczakiewicz- Multanowska A et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis. 51(9), 997-1004 (2010).
16. Kendal AP. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 13(5), 591-609 (1997). (Pubitemid 27306181)
17. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405-1412 (1998). (Pubitemid 28221981)
18. Vesikari T. Emerging data on the safety and efficacy of influenza vaccines in children. Pediatr. Infect. Dis. J. 27(Suppl. 11), S159-S161 (2008).
19. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr. Infect. Dis. J. 29(9), 806-811 (2010).
20. Petrovsky N, Ross TM. Challenges in improving influenza vaccine protection in the elderly. Expert Rev. Vaccines 10(1), 7-11 (2011).
21. El'shina GA, Gorbunov MA, Bektimirov TA et al. The evaluation of the reactogenicity, harmlessness and prophylactic efficacy of Grippol trivalent polymer-subunit influenza vaccine administered to schoolchildren. Zh. Mikrobiol. Epidemiol. Immunobiol. 2, 50-54 (2000).
22. Herzog C, Hartmann K, Kunzi V et al. Eleven years of Inflexal V - a virosomal adjuvanted influenza vaccine. Vaccine 27(33), 4381-4387 (2009).
23. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563-571 (2009).
24. Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines 9(12), 1385-1398 (2010).
25. Gasparini R, Schioppa F, Lattanzi M et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int. J. Clin. Pract. 64(4), 432-438 (2010).
26. Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus nonadjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
27. European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy. Euro Surveill. 15(38), pii: 19670 (2010).
28. Montastruc JL, Durrieu G, Rascol O. Pandemrix degrees, (H1N1)v influenza and reported cases of narcolepsy. Vaccine DOI:10.1016/j.vaccine.2010.12.092 (2011) (Epub ahead of print).
29. Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-2011. MMWR Morb. Mortal. Wkly Rep. 59(31), 989-992 (2010).
30. Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill. 15(37), 19661 (2010).